(66 days)
The DYNASTY® BIOFOAM® Shells are intended for use in cementless total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients.
Indications for Use
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis;
- correction of functional deformity; and,
- revision procedures where other treatments or devices have failed.
The DYNASTY® BIOFOAM® Shell is intended for cementless hip arthroplasty.
Design features of the shells are summarized below:
- Shells manufactured from Titanium alloy substrate, coated with BIOFOAM® coating manufactured from commercially pure (CP) titanium
- Solid shell sizes: 46mm-68mm outer diameter
- Three different hole patterns:
- 10-hole shell sizes: 46mm-76mm outer diameter
- 3-hole shell sizes: 46mm-68mm outer diameter
- 5-hole shell sizes: 46mm-50mm outer diameter
The DYNASTY® BIOFOAM® Shells are identical to previously cleared devices, except that the subject device posses different screw hole patterns. Additionally, the DYNASTY® BIOFOAM® Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the DYNASTY® BIOFOAM® Shells are equivalent to predicate devices.
The provided text is related to a 510(k) summary for a medical device called the DYNASTY® BIOFOAM® Shell, an acetabular cup for hip arthroplasty. The document describes the device, its intended use, and its substantial equivalence to predicate devices. However, it does not describe any clinical study or testing with acceptance criteria and reported device performance in the way a typical AI/ML device submission would.
The core of this submission is based on substantial equivalence to previously cleared devices (DYNASTY® Acetabular System K082924). The key statement that replaces a detailed performance study is:
"The DYNASTY® BIOFOAM® Shells are identical to previously cleared devices, except that the subject device posses different screw hole patterns. Additionally, the DYNASTY® BIOFOAM® Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the DYNASTY® BIOFOAM® Shells are equivalent to predicate devices."
And:
"The safety and effectiveness of the DYNASTY® BIOFOAM® Shells are adequately supported by the substantial equivalence information, materials information, and analysis data provided within this Premarket Notification."
Therefore, I cannot provide the requested information about acceptance criteria or a study proving the device meets them because such a study, with the specific details requested, is not present in this 510(k) summary. The submission relies on demonstrating equivalence through design and limited engineering analysis (post-impaction analysis).
Here's a breakdown of why this information is missing based on the document:
- No new clinical study: The document explicitly states the device is "identical to previously cleared devices, except that the subject device posses different screw hole patterns." This indicates that a comprehensive, new clinical performance study, often required for novel devices or significant changes, was not performed or deemed necessary.
- Reliance on Predicate Device Performance: The safety and effectiveness are established by the substantial equivalence to the predicate device (DYNASTY® Acetabular System, K082924). The performance of the predicate device is implicitly accepted.
- Limited "Evaluation" mentioned: The only "evaluation" mentioned is "post-impaction analysis of clearance, form and frictional torque." This is an engineering/benchtop test, not a clinical study involving patients or expert review. The document does not provide specific acceptance criteria or results for this analysis beyond stating it indicates equivalence.
In summary, the provided text does not contain the information required to answer your specific questions regarding acceptance criteria and a study proving their fulfillment, as it describes a 510(k) submission based on substantial equivalence and engineering analysis rather than a clinical performance study.
{0}------------------------------------------------
F121544
3 6 2012
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807, this information serves as a Summary of Safety and Effectiveness for the use of the DYNASTY® BIOFOAM® Shell.
Submitted By:
Date:
Contact Person:
Proprietary Name:
Common Name:
Classification Name and Reference:
Wright Medical Technology, Inc. 5677 Airline Rd, Arlington TN, 38002 (800) 238-7188
May 10, 2012
Yuan Li Regulatory Affairs Specialist
DYNASTY® BIOFOAM® Shell
Acetabular Cup
888.3330 Hip joint metal/metal semi-constrained, with an uncemented acetabular component prosthesis Class III
Subject Product Code and Panel Code:
Orthopedics/87/K WA
Predicate Devices:
DYNASTY® Acetabular System 510(k)s: K082924
DEVICE INFORMATION
A. Intended Use
The DYNASTY® BIOFOAM® Shells are intended for use in cementless total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients.
Indications for Use
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio 1. acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis; 2.
-
- correction of functional deformity; and,
- revision procedures where other treatments or devices have failed 4.
The DYNASTY® BIOFOAM® Shell is intended for cementless hip arthroplasty.
B. Device Description
Design features of the shells are summarized below:
- Shells manufactured from Titanium alloy substrate, coated with BIOFOAM® coating . manufactured from commercially pure (CP) titanium
- Solid shell sizes: 46mm-68mm outer diameter .
. 1 of 2
{1}------------------------------------------------
- Three different hole patterns:
- 10-hole shell sizes: 46mm-76mm outer diameter ।
- 3-hole shell sizes: 46mm-68mm outer diameter l
- -5-hole shell sizes: 46mm-50mm outer diameter
The DYNASTY® BIOFOAM® Shells are identical to previously cleared devices, except that the subject device posses different screw hole patterns. Additionally, the DYNASTY® BIOFOAM® Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the DYNASTY® BIOFOAM® Shells are equivalent to predicate devices.
C. Substantial Equivalence Information
The indications for use of the DYNASTY® BIOFOAM® Shells are identical to the previously cleared predicate device. The design features and materials of the subject devices are substantially equivalent to those of the predicate devices. The fundamental scientific technology of the modified devices has not changed relative to the predicate devices. The safety and effectiveness of the DYNASTY® BIOFOAM® Shells are adequately supported by the substantial equivalence information, materials information, and analysis data provided within this Premarket Notification.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the circle is an abstract symbol that resembles an eagle or a stylized human figure.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Wright Medical Technology, Incorporated % Yuan Li, Ph.D Regulatory Affairs Specialist 5677 Airline Road Arlington, Tennessee 38002
JUL 30 2012
Re: K121544
Trade Name: DYNASTY® BIOFOAM® Shell Regulation Number: 21 CFR 888.3330 Regulation Name: Hip joint metal/metal semi-constrained, with an uncemented acetabular component prosthesis Regulatory Class: III Product Code: KWA Dated: March 31, 2011 Received: April 1, 2011
Dear Dr. Li:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must corply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
{3}------------------------------------------------
Page 2 - Yuan Li, Ph.D
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
folle M. Curiain
Mark N. Melkerso Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known):
Device Name: DYNASTY® BIOFOAM® Shell
Indications For Use:
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular 1. . necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis; 2.
- correction of functional deformity; and, 3.
- revision procedures where other treatments or devices have failed. 4.
The DYNASTY® BIOFOAM® Shell is intended for cementless hip arthroplasty.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Ashf
(Division Sign-Oft) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K121544
§ 888.3330 Hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis.
(a)
Identification. A hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis is a two-part device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that consist of a femoral and an acetabular component, both made of alloys, such as cobalt-chromium-molybdenum. The femoral component is intended to be fixed with bone cement. The acetabular component is intended for use without bone cement (§ 888.3027).(b)
Classification. Class III.(c)
Date PMA or notice of completion of PDP is required. A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before May 18, 2016, for any hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component that was in commercial distribution before May 28, 1976, or that has, on or before May 18, 2016, been found to be substantially equivalent to a hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component that was in commercial distribution before May 28, 1976. Any other hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.